Connect your AI

NovoCure NVCR Impairment Charges

Impairment Charges at other companies

MedtronicMDT

$0—

Fortrea Holdings Inc.FTRE

$0-100%

Other financials

Income statement

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

Market cap$1.7B-36.7%

Profitability

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is NovoCure's impairment charges?: NovoCure (NVCR) reported impairment charges of $712K in Q1 2026.
How has NovoCure's impairment charges changed year-over-year?: NovoCure's impairment charges decreased by 68.5% year-over-year, from $2.26M to $712K.
What is the long-term trend for NovoCure's impairment charges?: Over 4 years (2021 to 2025), NovoCure's impairment charges has grown at a 65.3% compound annual growth rate (CAGR), from $649K to $4.85M.
What does impairment charges mean?: Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.